During Tuesday’s Current trade, Shares of MannKind Corporation (NASDAQ:MNKD), gain 3.99% to $4.04.
MannKind Corporation (MNKD) declared the renewal of its shelf Registration Statement on Form S-3, as filed with the Securities and Exchange Commission, replacing the previous shelf which expired on August 31, 2015. Conpresently, MannKind also renewed its At-The-Market Issuance Sales Agreements with Meyers Associates, L.P. (now doing business as BP Capital, a division of Meyers Associates, L.P.) and with MLV & Co. LLC providing for sales, from time to time, of the Company’s common stock.
MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes in the United States. Its lead product is AFREZZA inhalation powder, an insulin to control high blood sugar in adult patients with type 1 and type 2 diabetes. MannKind Corporation was founded in 1991 and is headquartered in Valencia, California.
Shares of Monsanto Company (NYSE:MON), declined -0.64% to $95.13, during its current trading session.
The Climate Corporation, a division of Monsanto Company (MON), declared at Farm Progress Show the launch of its newly integrated platform - bringing existing product offerings into one seamless platform and launching new solutions to turn farm data into real value for farmers. Climate’s existing suite of digital tools will become the Climate FieldView™ digital platform, and the company will launch new functionality over the course of the next few weeks for the 2016 season to further support data-driven decision making on the farm.
Monsanto Company, together with its auxiliaries, provides agricultural products for farmers worldwide. It operates in two segments, Seeds and Genomics, and Agricultural Productivity. The Seeds and Genomics segment produces row crop seeds, counting corn, soybean, cotton, and canola seeds principally under the DEKALB, Channel, Asgrow, and Deltapine brands; and vegetable seeds comprising of tomato, pepper, melon, cucumber, pumpkin, squash, beans, broccoli, onions, lettuce, and other seeds under the Seminis and De Ruiter brands.
Baytex Energy Corp (USA) (NYSE:BTE), during its Tuesday’s current trading session decreased -0.56% to $5.30.
Baytex Energy Corp. (BTE) (BTE) is happy to declare that James Bowzer, President and CEO, will be presenting at the Barclays CEO Energy-Power Conference on Wednesday, September 9, 2015 at 9:05 am EDT (7:05 am MDT) in New York, New York.
Baytex Energy Corp., an oil and gas company, engages in the acquisition, development, exploitation, and production of oil and natural gas in the Western Canadian Sedimentary Basin and the United States. The company offers heavy oil, light oil, condensate, and natural gas liquids. As of December 31, 2014, it had proved reserves of 283 million barrels of oil equivalent (mmboe); and proved plus probable reserves of 432 mmboe. The company was founded in 1993 and is headquartered in Calgary, Canada.
Finally, Endo International plc - Ordinary Shares (NASDAQ:ENDP), gained 3.25%, to $75.37.
Endo International plc (ENDP) announced the appointment of Craig Paterson, M.D. as Chief Medical Officer. In this new role, Dr. Paterson will report to Susan Hall, Ph.D., Executive Vice President, Chief Scientific Officer and Global Head of Research & Development and Quality, and will be responsible for Endo’s global clinical development strategies, execution and lifecycle management as well as that all marketed products and assets under development meet the highest safety and quality standards. Prior to joining Endo, Dr. Paterson held senior level medical and clinical development positions at Salix Pharmaceuticals, King Pharmaceuticals and GlaxoSmithKline.
Endo International plc, a specialty healthcare company, focuses on branded and generic pharmaceuticals and devices worldwide. It operates through four segments: U.S. Branded Pharmaceuticals, U.S. Generic Pharmaceuticals, Devices, and International Pharmaceuticals. The U.S. Branded Pharmaceuticals segment provides various branded prescription products, counting Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Fortesta Gel, Supprelin LA, Valstar, Vantas, Sumavel DosePro, Aveed, and Natesto to treat and manage pain and conditions in urology, endocrinology, and oncology. The U.S. Generic Pharmaceuticals segment offers products in the pain administration, urology, CNS disorders, immunosuppression, oncology, women’s health, hypertension, generic lidocaine patch, and other markets.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
